

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Union Medical Healthcare Limited

香港醫思醫療集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2138)

CHANGE OF NON-EXECUTIVE DIRECTOR

The Board announces that, with effect from 24 April 2020:

- (1) Dr. Wang David Guowei has resigned as a non-executive Director of the Company; and
- (2) Dr. Wang Steven Dasong has been appointed as a non-executive Director of the Company.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Union Medical Healthcare Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Dr. Wang David Guowei (“**Dr. David Wang**”) has resigned as a non-executive Director of the Company (“**Director**”) with effect from 24 April 2020 due to his other job commitments which require more of his dedications. Dr. David Wang has confirmed that he has no disagreement with the Board and there are no other matters in relation to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) or the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to express its sincere gratitude to Dr. David Wang for his invaluable contributions to the Company during his tenure and wish him every success in the future.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board announces that Dr. Wang Steven Dasong (“**Dr. Steven Wang**”) has been appointed as a non-executive Director of the Company with effect from 24 April 2020.

Dr. Steven Wang, aged 51, is a senior managing director of Asia at OrbiMed Advisors LLC, an investment fund with a focus on healthcare industry. Prior to that, he was a managing director and team leader of the Pharmaceutical Sector at CITIC Private Equity Funds Management Co., Ltd (“**CITICPE**”) (中信產業基金). He has over 20 years of experience of working in top global investment banks and direct investment firms. Before joining CITICPE, Dr. Steven Wang was a managing director and head of APAC Healthcare Investment Banking at Credit Suisse. He previously held various senior positions at the investment banking department of UBS AG and Morgan Stanley in Hong Kong. He led a number of Asia healthcare and related

deals including the initial public offerings of Sinopharm Corporation Group Co., Ltd. (國藥控股股份有限公司), Luye Pharma Group Ltd. (綠葉製藥集團有限公司) and Rici Healthcare Holdings Ltd (瑞慈醫療服務控股有限公司), the privatization of WuXi AppTec Co., Ltd. (葯明康德新藥開發有限公司) and Simcere Pharmaceutical Group (先聲藥業集團), as well as Luye Pharma Group Ltd.'s acquisition of Acino. Before returning to China in 2007, Dr. Steven Wang worked for seven years in New York for multinational investment banks and multi-strategy hedge funds. Before his career in finance, Dr. Steven Wang was a senior research scientist in the research and development department of Schering-Plough Corporation (subsequently acquired by Merck & Co., Inc.), focusing on allergy and immunology with multiple published paper and patents. Dr. Steven Wang holds a Ph.D. in Medicinal Chemistry from the Johns Hopkins University, and a MBA in Finance (with distinction) from New York University. He is a Chartered Financial Analyst.

Dr. Steven Wang was a non-executive Director of a company listed on the Main Board of Stock Exchange, namely 3SBio Inc. (Stock Code: 1530) from 30 June 2017 to 8 October 2019.

The Company has entered into a letter of appointment with Dr. Steven Wang for an initial term of three years commencing from 24 April 2020. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company. Pursuant to the letter of appointment, Dr. Steven Wang will not receive any remuneration, which is determined with reference to the consensus with Dr. Steven Wang, the recommendation of the remuneration committee of the Company, his expected duties and responsibilities and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Dr. Steven Wang (i) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not hold any other positions with the Company or other members of the Group; (iii) did not hold any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iv) does not hold any other major appointment and qualifications; and (v) does not have any relationships with any Directors, senior management, substantial shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) or controlling shareholders (as defined in the Listing Rules) of the Company.

The Board would like to take this opportunity to extend a warm welcome to Dr. Steven Wang for joining the Board.

By Order of the Board
Union Medical Healthcare Limited
Raymond Siu
Company Secretary

Hong Kong, 24 April 2020

As at the date of this announcement, the executive Directors of the Company are Mr. Tang Chi Fai, Mr. Lee Gabriel, Mr. Lee Heung Wing and Mr. Wong Chi Cheung; the non-executive Directors are Mr. Luk Kun Shing Ben and Dr. Wang Steven Dasong, and the independent non-executive Directors are Mr. Ma Ching Nam, Mr. Look Andrew and Mr. Lam Chi Hang Josekin.

**For identification purpose only*